Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 1318
Patent Rights shall mean (i) U.S. Patent 6,204,257 (the Phenol Prodrug Patent), (ii) any corresponding foreign patent applications and patents, (iii) U.S. patent application 10/208647 (a pending continuation application claiming the priority date of the Phenol Prodrug Patent), and (iv) all divisions, continuations, continuations-in-part, patents of addition, and substitutions of, and all patents issuing on, any of the foregoing, together with all registrations, reissues, reexaminations or extensions of any kind with respect to any such patents, in each case to the extent the same claim and disclose subject matter in the Phenol Prodrug Patent and any patents issued thereon.
On June 11, 2002, Dr. Roger A. Rajewski and Dr. Michelle P. McIntosh submitted to KU and Licensor a certain invention disclosure questionnaire describing an invention referred to as Delivery of a Sedative/Anti-Emetic Compound Via Inhalation (the Inhalation Technology). The term Patent Rights shall also include – in addition to any rights that would otherwise be treated as Patent Rights under this Section 1.08 – (i) the draft patent application related to the Inhalation Technology, and any revisions thereof, in existence on the Third Amendment Effective Date (Existing Application), (ii) any patents issued thereon, (iii) all patents and patent applications claiming (or which could claim) priority therefrom including all divisions, continuations, continuations-in-part, patents of addition, and substitutions of any of the foregoing, (iv) any corresponding foreign patent applications and patents, and (v) all registrations, reissues, reexaminations or extensions of any kind with respect to any of the foregoing.
Product shall mean any pharmaceutical or veterinary products covered by one or more of the claims of an issued patent under the Patent Rights, but excluding Propofol Product.
Propofol Product shall mean prodrugs of propofol, their compositions, methods of use, and processes for making as claimed by the Patent Rights.
IPSCIO Record ID: 3154
U.S. Patent No. 6,204,257 – Water Soluble Prodrugs of Hindered Alcohols and Phenols (the Alcohol and Phenol Patent)
U.S. Patent No. 6,451,776 – Water Soluble Prodrugs of Hindered Alcohols and Phenols (the Alcohol and Phenol Patent II)
U.S. Patent No. 5,985,856 – Water Soluble Prodrugs of Secondary and Tertiary Amine Containing Drugs and Methods of Making Thereof (the Secondary and Tertiary Amine Patent)
IPSCIO Record ID: 28741
Propofol (INN, marketed as Diprivan by AstraZeneca) is a short-acting, intravenously administered hypnotic/amnestic agent.
Each of the Licensor and the Licensee shall pay to the other party royalties on their quarterly net sales of covered products that rely on any valid claims. For covered products sold by either Party or their respective Affiliates, the royalty rate shall be five percent of Net Sales
List of Licensor Patents
Enhanced delivery of antifungal agents
PEG-lipid conjugates for liposomes and drug delivery
W02010107487 Lipid-drug conjugates for drug delivery
W02010085347 10733728.9 PEG-lipid conjugates for increasing the solubility of drug compounds
IPSCIO Record ID: 1315